Top 10 Most Promising Company, Once Again

At the 11th annual Texas Life Science Forum, held on November 8, 2022, EMPIRI Inc. was once again recognized as one of the Rice Alliance Most Promising Life Science Companies for our E-Slice technology.

Hosted by BioHouston and Rice Alliance for Technology and Entrepreneurship, the Texas Life Sciences Forum presents panels and networking opportunities to grow the life sciences field.

It also hosted over 50 companies to pitch their solutions for improvement. Chosen by investors present, EMPIRI was the only company to repeat in the Top 10 (from the 10th annual event).

Awarded 2022 NIH/NCI R01 Grant

Humbled and thrilled to receive our NIH/NCI R01 grant!

It is a 5-year $3.07M grant for a prospective clinical trial with our E-Slice assay to predict Triple Negative Breast Cancer patient treatment responses to standard of care.

Huge thanks to collaborators Dr. Kyuson Yun, Houston Methodist/Weill-Cornell Med, and Dr. Naoto Ueno at MD Anderson Cancer Center. #E-Slice #NIH #NCI # R01 #TNBC #MDACC #HMRI #Breastcancer #Immunotherapy #Cancertreatment #Precisiononcology

Texas Life Science Forum "Most Promising Company" Award

We are excited and grateful to announce being awarded "Most Promising Company" following the pitch competition at the 2022 Texas Life Science Forum! #lifescience#precisionmedicine#oncology#biotech

030922 Empiri TLSF press release

.pdf

Download PDF • 28.32MB